The pan-cancer survey of distinct tumor types from patients revealed that TRIM69 was recurrently upregulated in nearly all tumors including pancreatic adenocarcinoma (PAAD), which also contained much higher levels of Ctnnb1 and Id2 than the normal controls (Supplemental Figure 4A). Here, TRIM69 is linked to pancreatic adenocarcinoma.